Artiva Biotherapeutics Inc
ARTV2.958USD
+0.128+4.53%
交易中 （美东）报价延迟15分钟
72.07M总市值
亏损市盈率 TTM
关于 Artiva Biotherapeutics Inc 公司
Artiva Biotherapeutics, Inc. 是一家临床阶段的生物技术公司，专注于为患有毁灭性自身免疫性疾病和癌症的患者开发基于自然杀伤 (NK) 细胞的疗法。该公司的候选产品源自供体细胞（同种异体）而非患者自身细胞（自体），并且是预先制造、冷冻储存并随时可运送到患者的治疗地点。其主要候选产品 AlloNK 正在与 B 细胞靶向单克隆抗体 (mAb) 联合用于治疗自身免疫性疾病和癌症患者，例如 LN、RA、PV、ANCA 相关性血管炎亚型 GPA/MPA、SLE 和 B-NHL。 AlloNK 是一种非转基因、冷冻保存的 NK 细胞疗法，目前正在进行一项针对 III 类或 IV 类狼疮性肾炎 (LN) 的 I/Ib 期试验，以及一项针对多种自身免疫适应症的研究者发起的篮子试验 (IIT) 中对与 B 细胞靶向 mAb 联合进行评估。
公司简介
公司代码ARTV
公司名称Artiva Biotherapeutics Inc
上市日期Jul 19, 2024
CEODr. Fred Aslan, M.D.
员工数量89
证券类型Ordinary Share
年结日Jul 19
公司地址5505 Morehouse Drive
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编92121
电话18582674467
网址https://www.artivabio.com/
公司代码ARTV
上市日期Jul 19, 2024
CEODr. Fred Aslan, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
43.35K
+333.50%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
3.75K
-96.59%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Dr. Alison Moore, Ph.D.
Dr. Alison Moore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Dr. Brian Daniels, M.D.
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
43.35K
+333.50%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
3.75K
-96.59%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
收入明细
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q1
FY2022
暂无数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月19日 周六
更新时间: 7月19日 周六
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
40.44%
GC Biopharma Corp
18.75%
5AM Ventures
9.66%
VR Adviser, LLC
6.61%
VenBio Partners LLC
4.92%
Other
19.62%
持股股东
持股股东
占比
RA Capital Management, LP
40.44%
GC Biopharma Corp
18.75%
5AM Ventures
9.66%
VR Adviser, LLC
6.61%
VenBio Partners LLC
4.92%
Other
19.62%
股东类型
持股股东
占比
Venture Capital
58.50%
Corporation
18.75%
Investment Advisor
13.06%
Investment Advisor/Hedge Fund
6.64%
Private Equity
4.92%
Hedge Fund
2.37%
Individual Investor
1.24%
Research Firm
0.43%
Sovereign Wealth Fund
0.12%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
102
25.86M
106.14%
+3.25M
2025Q1
101
26.68M
109.52%
+4.03M
2024Q4
89
26.90M
110.75%
+5.25M
2024Q3
74
26.42M
108.79%
+10.37M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
9.85M
40.44%
--
--
Mar 31, 2025
GC Biopharma Corp
4.57M
18.75%
+4.57M
--
Jul 22, 2024
5AM Ventures
2.35M
9.66%
--
--
Mar 31, 2025
VR Adviser, LLC
1.61M
6.61%
--
--
Mar 31, 2025
VenBio Partners LLC
1.20M
4.92%
-321.00K
-21.12%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.16M
4.74%
+189.32K
+19.60%
Mar 31, 2025
Capital World Investors
866.62K
3.56%
-48.76K
-5.33%
Mar 31, 2025
The Vanguard Group, Inc.
858.21K
3.52%
-8.71K
-1.00%
Mar 31, 2025
Franklin Advisers, Inc.
520.33K
2.14%
+26.00
+0.00%
Mar 31, 2025
Geode Capital Management, L.L.C.
410.46K
1.68%
+94.70K
+29.99%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Biotechnology ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
查看更多
iShares Biotechnology ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
ProShares Ultra Nasdaq Biotechnology
占比0%
ProShares Hedge Replication ETF
占比0%
Global X Russell 2000 ETF
占比0%
iShares Russell 2000 ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares UltraPro Russell2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
